Maxim Group analyst Michael Okunewitch has maintained their bullish stance on OCGN stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Okunewitch has given his Buy rating due to a combination of factors related to Ocugen’s promising clinical progress and strategic positioning. The company is advancing its pivotal studies for OCU400 in retinitis pigmentosa and OCU410ST in Stargardt disease, both of which are nearing completion of enrollment. This progress is expected to lead to significant data releases in 2026, which could act as catalysts for the stock.
Additionally, Ocugen’s approach to clinical trials, which includes the use of placebo control arms, aligns well with regulatory expectations, potentially reducing the risk of regulatory hurdles. The company’s financial position is also stable, with enough cash to fund operations into the second quarter of 2026. Furthermore, the recent regulatory developments in the ophthalmic space, such as the UK’s acceptance of a Conditional Marketing Authorization application for a similar treatment, suggest a favorable environment for Ocugen’s future filings. These factors, combined with Ocugen’s ambitious goal of targeting three BLA filings in three years, underpin the positive outlook and the increased price target of $8.00.
In another report released today, Noble Financial also reiterated a Buy rating on the stock with a $8.00 price target.
OCGN’s price has also changed dramatically for the past six months – from $0.715 to $1.380, which is a 93.01% increase.